Somatostatin analogue – HORMONES (Archive)

The effect of long-term somatostatin analogue treatment on free and total insulin-like growth factor (IGF) -I, -II and IGF binding protein -1, -2 and -3 serum levels in euthyroid patients with active thyroid eye disease

Posted on by

Gerasimos Krassas, Nikolaos Pontikides, Argyrios Dumas, Jan Frystyk, Jian-WenChen, Allan Flyvbjerg

The aim of this study was to investigate the effect of long-term somatostatin analogue (SM-a) treatment on serum levels of free (F) and total (T) insulin-like growth factor (IGF)-I, -II and IGF binding protein (IGFBP) – 1, -2 and -3 in euthyroid patients with active thyroid ophthalmopathy. For this purpose, we measured the above-mentioned parameters …

Disappearance of a GH secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal

Posted on by

Sarantis Livadas, Dimitrios J. Hadjidakis, Maria I. Argyropoulou, Maria Stamatelatou, Dimitrios Kelekis, Sotirios A. Raptis

Download PDF

Acromegaly is caused by excessive growth hormone secretion, usually from a pituitary adenoma. The use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. We are aware of only three reported cases of complete shrinkage of a pituitary adenoma after long-term analogue administration…